Dual-Domain α/β Chimeric Peptides for Low-Toxicity Plant Disease Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current disease management tools for bacterial diseases in fruit crops, such as Huanglongbing (HLB) and fire blight, are ineffective against bacterial resistance and pose safety concerns, leading to significant production losses.
Innovation Solution
Development of novel chimeric peptides composed of two different α/β peptide domains coupled by a linker, derived from plant innate immune proteins, which enhance bactericidal activity and stimulate plant immunity while minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics and chemicals are used for disease management, then bacterial infections can be suppressed initially, but bacterial resistance develops rapidly rendering the tools ineffective
Solution Approach 1:
The invention segments the antibacterial function into two distinct peptide domains (α-domain and β-domain) with different mechanisms of action. The α-domain targets membrane phospholipids while the β-domain targets cell wall synthesis, preventing single resistance mechanisms from neutralizing the entire therapeutic agent
Solution Approach 2:
The chimeric peptide functions as a composite therapeutic agent combining two different peptide domains with complementary antibacterial mechanisms. This composite structure allows the single molecule to attack bacteria through multiple pathways simultaneously, overcoming resistance that develops against single-mechanism antibiotics
2Reliability
If pathogenesis-related proteins are used to enhance host immunity, then plant defense is strengthened, but evolution of bacterial resistance renders the proteins ineffective
Solution Approach 1:
The chimeric peptide introduces local quality differentiation by incorporating two distinct functional domains with different antibacterial mechanisms within a single protein structure. The α-domain provides membrane disruption capability while the β-domain provides cell wall inhibition, creating localized functional diversity that prevents uniform bacterial resistance
Solution Approach 2:
The invention changes the functional parameters of the immune protein by combining two different peptide domains with distinct mechanisms of action. This parameter diversification (different molecular targets and modes of action) prevents bacteria from adapting to a single mechanism, thereby maintaining long-term effectiveness against evolving pathogens
3Reliability
If stronger antibiotics and chemicals are applied to overcome resistance, then bacterial infections are controlled, but safety concerns and toxicity increase
Solution Approach 1:
The chimeric peptide is derived by copying and combining natural plant defense peptide sequences (α-domain and β-domain) that already exist in the plant's innate immune system. This ensures the therapeutic agent is biocompatible and less toxic to the host plant and humans compared to synthetic antibiotics, while maintaining strong antibacterial activity
Solution Approach 2:
The invention utilizes the plant's own immune peptide sequences to construct the therapeutic agent, allowing the plant to recognize and tolerate the treatment. The chimeric peptide acts as a self-service immune enhancement rather than an external toxic substance, reducing harmful effects on the host and environment
Data Source
AI summary
The present invention includes the design and therapeutic application of novel α/β chimeric peptides formed by two different α/β segments coupled by a peptide linker. Through a combination of molecular modeling, bactericidal, and toxicity analyses the α/β chimeric peptides of the invention exhibit antibacterial effects in plants with low cytotoxicity in both plant and human cells.